Can aspirin use reduce the risk of pancreatic cancer:an updated systematic review and meta-analysis

Background:Chemoprevention effect of aspirin for pancreatic cancer(PC)remains unclear.Here we performed an updated systematic review and meta-analysis to investigate the real association between aspirin consumption and risk of PC.Methods:PubMed,Web of Science,EMBASE and the Cochrane Database were systematic searched to identify the potential studies.Odds ratio(ORs)with 95%confidence intervals(CIs)were applied to assess the strength of associations.Results:Thirteen studies and approximately 28,440 participants were included.Aspirin significantly reduced the incidence of PC(OR,0.82;95%CI,0.73-0.93)in case-control studies.However,the overall results did not reveal an obvious association(OR,0.92;95%CI,0.74-1.16).Both low-dose(OR=0.86)and high-dose(OR=0.80)aspirin intake showed prevention effect.In addition,low frequency(OR,0.87;95%CI,0.73-1.05)and high frequency(OR,0.84;95%CI,0.69-1.03)seemed to be equally associated with decreased risk for PC.Aspirin consumption longer than 10 years use seems to have better effect(OR,0.73;95%CI,0.51-1.04)than shorter aspirin use(OR,0.94;95%CI,0.77-1.15).Conclusions:Our study indicated that aspirin use might be associated with decreased risk of PC,especially at high doses.But we still need to be cautious when interpreting the results.